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Background. We retrospectively analyzed whether poor diﬀerentiation is the independent prognostic factor for thyroid carcinoma
or not. Methods. The subjects were 29 patients with PDTC who were treated between April 1996 and March 2006 to compare
with those of well-diﬀerentiated papillary carcinoma patients (n = 227). Results. The relapse free (RFS), distant relapse-free
survival and cause-speciﬁc survival, rates were signiﬁcantly lower in patients with PDTC (P<. 0001, P<. 001, and P<. 05).
After classiﬁcation into focal (<10%) and diﬀuse type (over 10%) of PDTC, there were no signiﬁcant diﬀerences in RFS and
cause-speciﬁc survival due to component type or proportion of poorly diﬀerentiated component. On multivariate analysis, poor
diﬀerentiation (P<. 0005, RR = 4.456, 95% CI; 1.953–10.167) and extrathyroidal inﬁltration (P<. 05, RR = 2.898, 95% CI; 1.278–
6.572) showed a signiﬁcant impact on DFS, and poor diﬀerentiation (P<. 05, RR = 9.343, 1.314–66.453) and age (P<. 005, RR =
1.306, 1.103–1.547) signiﬁcantly impacted cause-speciﬁc survival. Conclusion.P o o rd i ﬀerentiation was an independent factor for
survival. Distant relapse was signiﬁcantly more common among PDTC patients, and systemic therapy might be warranted.
1.Introduction
Poorly diﬀerentiated thyroid carcinoma (PDTC) was ﬁrst
proposed by Sakamoto et al. in 1983 [1] and separately
categorized by the 2004 WHO classiﬁcation of Endocrine
Tumors [2]. Based on the Turin proposal in 2006, PDTC
demonstrates solid, trabecular, and insular components,
the absence of conventional nuclear patterns of papillary
carcinoma, and the presence of at least one of the following
features: convoluted nuclei, mitotic activity, or necrosis [3].
Some reports have shown a worse prognosis for PDTC
to be compared with that of well-diﬀerentiated thyroid
carcinoma (WDTC). Anaplastic thyroid carcinoma is a well-
known to be lethal regardless of the proportion of incident
anaplastic carcinoma within well-diﬀerentiated carcinoma.
Even when PDTC is a minor component within the tumor,
an aggressive behavior has been reported [4, 5]. However, it
has been reported that minor focal distribution of an insular
component does not aﬀect the prognosis [6, 7]. PDTCs
are divided into focal PDTC (<10%) and diﬀuse PDTC
(>10%) based on the proportion of the poorly diﬀerentiated
component [2]. Thus, the clinical behaviors of poorly
diﬀerentiated thyroid carcinoma remain controversial, and it
isunclearwhethertheproportionofthepoorlydiﬀerentiated
component aﬀects its prognosis.
We retrospectively analyzed the outcome of patients with
poorly diﬀerentiated thyroid carcinoma who were initially
treated in our hospital between April 1996 and March 2006.
Furthermore, we compared ﬁndings with those of well-
diﬀerentiated papillary carcinoma patients who underwent
surgery during the same period in order to evaluate the
characteristics of the subjects.
2. Patients andMethods
This is a cohort study to identify the characteristics of
patients with PDTC treated by primary surgery in our
hospital between April 1996 and March 2006. Clinico-
pathological ﬁndings were compared with those of WDTC
patients who underwent surgery during the same period2 ISRN Endocrinology
Table 1: The clinical characteristics of PDTC and WDTC patients.
Poorly diﬀerentiated
carcinoma
Well-diﬀerentiated
papillary carcinoma
P value
Gender (M/F) 7/22 44/183 n.s.
Age (median; range) 57 (20–83) 54 (11–77) n.s.
Tumor size (cm) 3.171.8 1.9771.3 P<. 0001
Ex∗1 0 13 129 n.s., P = .078
17 6 5
29 3 3
Lymph node
involvement∗2 08 7 3 n.s.
1a 15 82
1b 6 68
Pathological subtypes
Solid 8
— — Insular 5
Trabecular 7
Solid & trabecular 9
Recurrent sites Lymph node 7 13 —
Lung 2 6
Bone 0 1
Others 2 2
Median followup Period
(months) 75.9 89.3 n.s.
∗1 EX1: inﬁltrating to adjacent muscle and/or fat tissue, EX2: inﬁltrating to adjacent organs such as trachea, esophagus, and so forth.
∗2 1a: central cervical lymph node involvement, 1b: lateral cervical lymphnode involvement.
in order to evaluate the clinical characteristics of these
subjects. The initial surgical procedures were ipsilateral
hemithyroidectomy for patients with tumors over 1.0cm
in diameter and total lobectomy for those with tumors
smaller than 1.0cm in diameter. Total thyroidectomy was
performed for patients with distant metastasis, with tumor
invasion of adjacent organs or with tumor conﬁned to
bilateral lobes on preoperative examination and intraop-
erative determination. All our papillary thyroid carcinoma
patients undergo modiﬁed radical dissection of the cervical
lymph nodes (central component only or central and lateral
components). We do not routinely administer radioiodine as
adjuvant therapy; however, thyrotropin (TSH) suppression
therapy was achieved with thyroxine (T4) during the course
of the disease as an adjuvant therapy after surgery for all
enrolled patients. All the patients were followed by checking
serum thyroglobulin value, cervical palpation, and chest ﬁlm
every 6 months postoperatively. The relapse-free and distant
relapse-free survivals were deﬁned as survival without any
recurrence and without any distant recurrence, respectively.
The choice of standard surgical procedures and not useing
postoperative routine radioiodine therapy in our hospital are
not unique in Japan [8, 9].
PDTC was diagnosed when poorly diﬀerentiated sub-
types were recognized regardless of the proportion. The
ratio of each PDTC component to WDTC was calculated
in order to divide the two groups into the focal (<10%) or
diﬀuse (>10%) type. Informed consent was obtained from
all enrolled patients. The clinical data have been deidentiﬁed
under anonymity, and patient information was protected
in this retrospective study. The Mann-Whitney U test,
the Kaplan-Meier method, and Cox’s proportional hazard
model were used for analyses, and P<. 05 was considered
signiﬁcant.
3. Results
3.1. Clinical Characteristics. Clinical characteristics are
showninTable 1.ThepatientswithPDTCwere29,theywere
treated during that period (control patients: 227). Of these
29 patients, there were 7 men and 22 women. The median
patient age was 57, and mean primary tumor size was 3.1
± 1.8cm. The primary tumor in patients with PDTC was
signiﬁcantly larger than that in those with well-diﬀerentiated
tumor (P<. 0001). Histological lymph node involvement
and extrathyroidal inﬁltration (EX) were positive in 21
(72.4%) and 16 (55.2%) patients with PDTC, respectively.
The distribution of three subtypes of poorly diﬀerenti-
ated thyroid carcinoma was 27.6% solid type, 17.2% insular
type, 24.1% trabecular type, and 31.0% solid and trabecular
type. The distribution of focal and diﬀuse components
of PDTC was 37.9% (11 of 29) and 62.1% (18 of 29),
respectively.
Table 2 shows the clinical characteristics of the focal and
diﬀusetypesofPDTC.Therewasnodiﬀerencebetweenfocal
and diﬀuse types in age, gender, lymph node involvement,ISRN Endocrinology 3
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Figure 1: The 10-year relapse-free survival rate was 32.1% in poorly diﬀerentiated carcinoma (8.0% in well-diﬀerentiated carcinoma, P<
.05). Using the Kaplan-Meier method, relapse-free and distant relapse-free survival rates were signiﬁcantly lower among patients with poorly
diﬀerentiated carcinoma (P<. 0001 and P<. 001, resp.).
Table 2: The clinical characteristics of patients with focal and diﬀuse component of PDTC.
Focal component Diﬀuse component P value
Number 15 14 —
Gender (M/F) 4/15 7/14 n.s.
Age (median; range) 57 (20–71) 58 (22–83) n.s.
Tumor size (cm) 2.7571.4 3.3972.1 n.s.
Ex∗10 9 4 P<. 01
15 2
21 8
Lymph node involvement∗20 5 3 n . s .
1a 8 7
1b 2 4
Pathological subtypes
Solid 4 3
n.s. Insular 2 3
Trabecular 4 2
Solid & trabecular 5 4
Local recurrence P4 5 n.s.
N1 1 9
Distant recurrence P1 2 n.s.
N1 41 2
P: positive, N: negative
∗1 EX1: inﬁltrating to adjacent muscle and/or fat tissue, EX2: inﬁltrating to adjacent organs such as trachea, esophagus, and so forth.
∗2 1a: central cervical lymph node involvement, 1b: lateral cervical lymphnode involvement.
tumor size, or pathological type of PDTC. However, the ratio
of extrathyroidal inﬁltration to an adjacent organ such as the
trachea and/or esophagus (EX2) was 57.1% (8 of 14) in the
diﬀuse type and 7.1% (1 of 15) in the focal type. There was a
signiﬁcant diﬀerence in the presence of EX2 (P<. 01).
3.2. Outcome. Median followup periods for PDTC and
WDTC patients were 75.9 and 89.3 months, respectively.
The 10-year recurrence rate was 32.1% for poorly diﬀer-
entiated carcinoma (8.0% for well-diﬀerentiated carcinoma,
P<. 05). Using the Kaplan-Meier method, relapse-free and
distant relapse-free survival rates were signiﬁcantly lower
in PDTC (P<. 0001 and P<. 001, resp., Figure 1). Of
29 patients with PDTC, two died of disease, and of 227
with WDTC, four died of disease. The 10-year cause-speciﬁc
survival rates were 89.3% for PDTC and 98.7% for WDTC.4 ISRN Endocrinology
Table 3: The results of multivariate analyses for DFS and cause-speciﬁc survival.
(a) For DSF
Factors Relative risk C.I. P value
Poor diﬀerentiation 4.456 1.953–10.167 P<. 0005
Extrathyroidal inﬁltration 2.898 1.278–6.572 P<. 05
(b) For cause-speciﬁc survival
Factors Relative risk C.I. P value
Poor diﬀerentiation 9.343 1.314–66.453 P<. 05
Older age 1.306 1.103–1.547 P<. 005
C.I.: conﬁdence interval
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Figure 2: Of 29 patients with poorly diﬀerentiated carcinoma,
two died of disease, and of 227 with well-diﬀerentiated carcinoma,
four died of disease. The 10-year cause-speciﬁc survival rates were
89.3% for PDTC and 98.7% for WDTC. Despite the low number of
disease-relateddeaths,therewasasigniﬁcantdiﬀerencebetweenthe
two groups (P<. 05).
Despite the low number of disease-related deaths, there was
a signiﬁcant diﬀerence between groups (P<. 05, Figure 2).
In the focal and diﬀuse type, there were no signiﬁcant
diﬀerences in DFS and cause-speciﬁc survival. However,
patients who died of disease were only found in diﬀuse
type.
Table 3 shows the results of multivariate analysis for
DFS and cause-speciﬁc survival in all patients (n = 256).
Analyzed factors were age, gender, tumor size, lymph node
involvement,extrathyroidalinﬁltration,poordiﬀerentiation,
and population of poor diﬀerentiation. Poor diﬀerentiation
(P<. 0005, RR = 4.456, 95% CI; 1.953–10.167) and
extrathyroidal inﬁltration (P<. 05, RR = 2.898, 95% CI;
1.278–6.572) were signiﬁcant factors for DFS. Furthermore,
poor diﬀerentiation (P<. 05, RR = 9.343, 1.314–66.453) and
older age (P<. 005, RR = 1.306, 1.103–1.547) signiﬁcantly
aﬀected cause-speciﬁc survival. The proportion of PDTC did
not inﬂuence DFS and cause-speciﬁc survival.
4. Discussion
In Japan, the application of surgical methods and use of
postoperative radioiodine therapy for WDTC are unique
compared with other countries [8, 9]. In our ﬁndings, the
10-year cause-speciﬁc survival rates were 89.3% for PDTC
and 98.7% for WDTC. In other countries, 10-year and 40-
year relative survival rate was reported as 93% [10]a n d
94% [11], respectively. Our data is not inferior to those
of other countries. Actually, it is still controversial that
total thyroidectomy followed by postoperative radioiodine
therapy and TSH suppressive therapy is associated with
improved survival for all patients with WDTC [12, 13]. For
high-risk patients with WDTC, this standard therapy might
be beneﬁcial [12, 13].
Poorly diﬀerentiated thyroid carcinoma consists of three
pathological subtypes, solid, insular, and trabecular [2]. In
2006, a consensus meeting was held in Turin and PDTC
was discussed by experts from many diﬀerent countries.
Volante and Papotti published a summary of the established
consensus and remaining controversies [14]. According to
the established consensus, solid, trabecular, and insular
growth patterns should be predominant [14]. Ito et al. have
shown the diﬀerences among three deﬁnitions proposed by
Sakamotoetal.[1],WHO[2],andTurin[12]forPDT C[15].
Many reports have demonstrated a poorer survival
among poorly diﬀerentiated carcinoma patients than among
those with well-diﬀerentiated carcinoma [4–7, 16]. In our
study, patients with PDTC also showed signiﬁcantly poorer
outcome compared to that of those with WDTC. Especially,
PDTC patients showed a signiﬁcantly worse outcome in
distant relapse-free survival. On multivariate analysis, poor
diﬀerentiationwasoneoftheindependentprognosticfactors
for both DFS and cause-speciﬁc survival. Each relative risk
was 4.456 and 9.343, respectively. Similar to our ﬁndings,
poor diﬀerentiation has previously been demonstrated to be
an independent factor for survival [17].
Thus, poor diﬀerentiation is associated with a worse
prognosis. However, it remains controversial whether the
proportion showing poor diﬀerentiation (focal or diﬀuse)
aﬀects the outcome of patients with PDTC. In our study,
the distribution of patients showing focal and diﬀuse com-
ponentsofPDTCwas37.9%(11of29)and62.1%(18of29),
respectively. Even when PDTC is a minor component ofISRN Endocrinology 5
the tumor, an aggressive behavior has been demonstrated
[4, 5]. However, it has been reported that a minor focal
distribution of the insular component does not aﬀect the
prognosis [6, 7]. In our series, there was no signiﬁcant
diﬀerence in DFS or cause-speciﬁc survival between patients
with focal or diﬀuse PDTC. However, patients with diﬀuse
PDTC showed a signiﬁcantly higher ratio of extrathyroidal
inﬁltration. This might be an indication of aggressive local
disease in diﬀuse type of PDTC. Despite the low number
of disease-related deaths in this series, patients with PDTC
showed a signiﬁcantly rate of disease-related death.
Decreasedthyrotropinreceptor(TSH-R)hasbeenshown
in PDTC compared with that in WDTC [18]. The TSH-
R expression level has been reported to correlate with
unfavorable clinical features [19]. There are some reports of
in vitro studies demonstrating a lower expression of sodium
iodide symporter in poorly diﬀerentiated thyroid carcinoma
cell lines [20, 21]. Thus, the reduction of thyroid diﬀeren-
tiation markers such as TSH-R, sodium iodide symporter,
and thyroglobulin might mean worse prognosis. Although
it remains unclear whether radioiodine therapy is useful
in PDTC [8], distant relapse and local invasiveness were
signiﬁcantly more common in PDTC patients. Therefore, for
patients with PDTC, systemic treatment might be warranted
during the initial therapy as high-risk patients.
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